These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33431672)

  • 1. A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease.
    Rebelo D; Oliveira F; Abrunhosa A; Januário C; Lemos J; Castelo-Branco M
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic exposure to dopamine agonists affects the integrity of striatal D
    Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
    Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.
    Farkas S; Nagy K; Jia Z; Harkany T; Palkovits M; Donohou SR; Pike VW; Halldin C; Máthé D; Csiba L; Gulyás B
    Brain Res Bull; 2012 Apr; 87(6):504-10. PubMed ID: 22421165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
    J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.
    Sawamoto N; Piccini P; Hotton G; Pavese N; Thielemans K; Brooks DJ
    Brain; 2008 May; 131(Pt 5):1294-302. PubMed ID: 18362097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic modulation of resting-state functional connectivity in de novo patients with Parkinson's disease.
    Baik K; Cha J; Ham JH; Baek GM; Sunwoo MK; Hong JY; Shin NY; Kim JS; Lee JM; Lee SK; Sohn YH; Lee PH
    Hum Brain Mapp; 2014 Nov; 35(11):5431-41. PubMed ID: 24938993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging in Parkinson's disease: the role of monoamines in behavior.
    Brooks DJ; Piccini P
    Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.
    Piccini P; Brooks DJ; Björklund A; Gunn RN; Grasby PM; Rimoldi O; Brundin P; Hagell P; Rehncrona S; Widner H; Lindvall O
    Nat Neurosci; 1999 Dec; 2(12):1137-40. PubMed ID: 10570493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
    Rinne JO; Portin R; Ruottinen H; Nurmi E; Bergman J; Haaparanta M; Solin O
    Arch Neurol; 2000 Apr; 57(4):470-5. PubMed ID: 10768619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Stark AJ; Smith CT; Petersen KJ; Trujillo P; van Wouwe NC; Donahue MJ; Kessler RM; Deutch AY; Zald DH; Claassen DO
    Neuroimage Clin; 2018; 18():433-442. PubMed ID: 29541577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
    Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
    Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
    Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
    Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.
    Sacheli MA; Neva JL; Lakhani B; Murray DK; Vafai N; Shahinfard E; English C; McCormick S; Dinelle K; Neilson N; McKenzie J; Schulzer M; McKenzie DC; Appel-Cresswell S; McKeown MJ; Boyd LA; Sossi V; Stoessl AJ
    Mov Disord; 2019 Dec; 34(12):1891-1900. PubMed ID: 31584222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.